Immune Network Ltd. Announces Intent to Acquire Oral Vaccine Technology Platform
16 Setembro 2010 - 10:58AM
Immune Network Ltd. (Pink Sheets:IMMFF), advises the Company has a
plan to acquire patented oral vaccine technology developed and
clinically validated by the privately-held Immunitor group of
companies and affiliates. As a pre-condition of this acquisition,
the Company will need to update its regulatory filings and deal
with outstanding accounting and legal issues, in addition to full
due-diligence analysis of the respective companies.
Immunitor's technology is based on decades of research and is
positioned to forever change the way vaccines are made and
administered. The acquisition will give Immune Network an
exciting opportunity to commercialize existing oral vaccines for
high-impact infectious diseases such as influenza, tuberculosis,
hepatitis and HIV. The acquisition will additionally give
Immune Network access to Immunitor's existing manufactured line of
orally administered, broad-spectrum, prophylactic and therapeutic
tableted vaccines designed to protect against microbial and fungal
infections and for immunotherapy of non-infectious diseases such as
cancer and autoimmune and/or metabolic disorders comprising
allergy, diabetes, obesity and atherosclerosis. Immunitor's
advanced innovative technology can dramatically shorten vaccine
production timelines and offers tremendous potential to improve and
protect human health globally.
Websites for Immune Network Ltd. (www.immune-network.com) and
for Immunitor (www.immunitor.com) are currently being updated and
expanded. The Immunitor site will provide access to the many
scientific and clinical publications about the technology. For
this acquisition to proceed, funding will be needed for the
prerequisite activities in the Company and there can be no
assurances of the availability or terms of such
funding. Further details of the proposed transaction, and
changes in the composition of the Board of Directors of the
Company, will be made public in press releases and on the websites
pending further progress with due-diligence assessment of both
companies and final terms being established.
The Immune Network Ltd logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
info@immunitor.com
immff@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Omni Bridgeway Ltd (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Immune Network Ltd